Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority tria
about
Role of insulin in the type 2 diabetes therapy: past, present and futureConcepts and clinical use of ultra-long basal insulinInsulin degludec and insulin aspart: novel insulins for the management of diabetes mellitusSafety, efficacy, and early clinical experience of insulin degludec in Japanese people with diabetes mellitus: A first-year report from JapanLong-term safety and efficacy of insulin degludec in the management of type 2 diabetesA novel, long-acting glucagon-like peptide receptor-agonist: dulaglutideMechanisms of hypoglycemia unawareness and implications in diabetic patientsCardiovascular effects of basal insulinsThe evolution of insulin glargine and its continuing contribution to diabetes careModern basal insulin analogs: An incomplete storyTreatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitorsPatient safety and minimizing risk with insulin administration - role of insulin degludecUpdate on the treatment of type 2 diabetes mellitusSafety and efficacy of insulin glargine 300 u/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysisClinical utility of insulin and insulin analogs.Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future.Hypoglycemia Event Rates: A Comparison Between Real-World Data and Randomized Controlled Trial Populations in Insulin-Treated Diabetes.Cost-effectiveness of switching to insulin degludec from other basal insulins: evidence from Swedish real-world data.Insulin Degludec in Clinical Practice: A Review of Japanese Real-World Data.Insulin degludec compared with insulin glargine in insulin-naïve patients with type 2 diabetes: A 26-week, randomized, controlled, Pan-Asian, treat-to-target trial.Insulin Degludec Aspart: The First Co-formulation of Insulin AnaloguesIdentifying and meeting the challenges of insulin therapy in type 2 diabetes.Can a new ultra-long-acting insulin analogue improve patient care? Investigating the potential role of insulin degludec.A review of the pharmacological properties of insulin degludec and their clinical relevance.Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial.Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials.A comparison of health-related quality of life (health utility) between insulin degludec and insulin glargine: a meta-analysis of phase 3 trials.Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes.Injectable Coformulations in DiabetologyComparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial.IDegLira Versus Alternative Intensification Strategies in Patients with Type 2 Diabetes Inadequately Controlled on Basal Insulin Therapy.Design of non-standard insulin analogs for the treatment of diabetes mellitusInsulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long)Role of Emerging Insulin Technologies in the Initiation and Intensification of Insulin Therapy for Diabetes in Primary Care.Efficacy and safety of insulin degludec in Japanese patients with type 1 and type 2 diabetes: 24-week results from the observational study in routine clinical practice.Insulin degludec improves health-related quality of life (SF-36® ) compared with insulin glargine in people with Type 2 diabetes starting on basal insulin: a meta-analysis of phase 3a trials.The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in iEfficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extensionA Multinational, Randomized, Open-label, Treat-to-Target Trial Comparing Insulin Degludec and Insulin Glargine in Insulin-Naïve Patients with Type 2 Diabetes Mellitus.Insulin degludec once-daily in type 2 diabetes: simple or step-wise titration (BEGIN: once simple use).
P2860
Q22241148-54830323-DC22-4D29-B288-7FC6BFA43809Q26770354-23E8A3F9-DC64-4436-8793-CA34A98434DFQ26777076-6192562C-2E93-40AA-8B4C-0B65AAC8364CQ26778763-EF66FC84-DB0B-4F90-9668-E2B574A84D0DQ26784381-7CC2F7CB-1B3E-4732-85DB-28B09C65DC1BQ26796417-A21D8F52-2F82-4A48-B039-99712047AEA2Q26799608-73357F77-FA29-46F5-839F-A9B89A58A43FQ26800249-4DE6F857-49EB-48B3-B6F8-EA2F3FCE0600Q26999454-38D4CDCA-0CA2-43B7-B828-CDAD85B77E06Q27015047-BA5039EE-EFB6-423F-B516-5C26DBEEA4DDQ27021870-92815329-18D6-4F10-94EB-9BDB21058DF3Q27025548-EB717A92-1311-4C34-81FE-0FB3A9AFB912Q28073342-84B96684-6413-44AA-91FD-3971F554D261Q28078467-0C3F0A12-AD05-4374-AB38-A2C0237DAC8CQ30429358-C198C944-1702-482B-9CE6-A103A035CDCCQ30597265-79A99029-7EEC-4220-9E4C-4FC9766EB249Q31046934-A839BD97-68BF-4917-ACD8-392EB0F9EAAAQ31152059-68A4DA80-0A3C-44CB-83DF-EEFE8631FAB6Q31154873-29721BCC-1B2D-4305-A1DA-FA357A777CD8Q33607759-0700BAAB-05E7-40E8-90AD-453926AF2C13Q33785168-EBAD8B64-6D0C-4CCF-A01F-5F011A4B000AQ33863413-E2241EE0-9AD1-4AA8-B7FD-EB3C534E7060Q34311240-D15797CD-A031-4F6E-A923-D2D6C29272E3Q34436383-525B0017-1116-4CC7-B996-284EE183DB1BQ34543035-58A1B4BD-F9F0-447B-9C01-D70C9175ECD5Q34726423-8A3ACC31-7347-4694-8427-78141F117924Q34981168-1623025D-A042-42D5-A770-A444ED49B8B2Q35549468-EAF44709-B852-4938-97F0-F073E74CF5ECQ35772586-C9E59099-5E4A-43D8-923B-E54F066EB413Q36103732-16715171-2E74-4842-BEC9-058C7B5508D4Q36360100-C579ECA1-8F40-44F5-9107-0A9FA7608692Q36374363-76DCF994-75BA-4A32-8DED-74BF7B075912Q36426912-E7337927-BA67-465D-9193-56A459B5EBABQ36467597-FD963E74-C9CB-420B-BEA7-FDD943E42B1EQ36477634-9F431B8E-62BB-4EA5-AB03-B41EC22D1D5EQ36629179-44210D9B-808B-4083-877D-93A4F4617163Q36720304-A9D975EE-6BB4-44B6-AF24-4A1D5729193CQ36730246-C613D939-9F05-43E7-8142-91E51355405DQ36924024-D8B3FD9F-27E1-4B39-9FC6-B9AD5787E469Q37061142-9FC45B63-AFB2-4B9A-9FCD-CC504EE9EEC3
P2860
Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority tria
description
2012 nî lūn-bûn
@nan
2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Insulin degludec, an ultra-lon ...... to-target non-inferiority tria
@ast
Insulin degludec, an ultra-lon ...... to-target non-inferiority tria
@en
Insulin degludec, an ultra-lon ...... to-target non-inferiority tria
@nl
type
label
Insulin degludec, an ultra-lon ...... to-target non-inferiority tria
@ast
Insulin degludec, an ultra-lon ...... to-target non-inferiority tria
@en
Insulin degludec, an ultra-lon ...... to-target non-inferiority tria
@nl
prefLabel
Insulin degludec, an ultra-lon ...... to-target non-inferiority tria
@ast
Insulin degludec, an ultra-lon ...... to-target non-inferiority tria
@en
Insulin degludec, an ultra-lon ...... to-target non-inferiority tria
@nl
P2093
P1433
P1476
Insulin degludec, an ultra-lon ...... to-target non-inferiority tria
@en
P2093
Alan J Garber
Allen B King
Ann Marie Ocampo Francisco
Lars A Endahl
Manuel Muñoz-Torres
Mustafa K Balci
NN1250-3582 (BEGIN BB T2D) Trial Investigators
Priscilla Hollander
Seamus Sreenan
Stefano Del Prato
P304
P356
10.1016/S0140-6736(12)60205-0
P407
P577
2012-04-01T00:00:00Z